Does Rallies show 13F holders for RLMD?

Yes. Rallies tracks hedge fund and 13F ownership data for RLMD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RLMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RLMD. It does not provide personalized investment advice.

RLMD (Relmada Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Relmada Therapeutics, Inc. Common Stock (RLMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RLMD trades at $6.76 with a market cap of $665.00M and a P/E ratio of -4.83. RLMD moved +1.99% today. Year to date, RLMD is +69.50%; over the trailing twelve months it is +1101.01%. Its 52-week range spans $0.24 to $8.00. Analyst consensus is strong buy with an average price target of $15.00. Rallies surfaces RLMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RLMD stock?

Hedge funds tracked by Rallies that own RLMD include Orbimed Advisors and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Relmada Therapeutics, Inc. Common Stock.

RLMD Key Metrics

Key financial metrics for RLMD
Metric	Value
Price	$6.76
Market Cap	$665.00M
P/E Ratio	-4.83
EPS	$-1.45
Dividend Yield	0.00%
52-Week High	$8.00
52-Week Low	$0.24
Volume	9
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-57.39M
Gross Margin	0.00%

Top Hedge Funds Holding RLMD

Orbimed Advisors holds 4.72M shares of RLMD, changed +80.64% as of Mar 31, 2026.
Mangrove Partners holds 71.70K shares of RLMD, changed +161.89% as of Mar 31, 2026.

Latest RLMD News

Relmada Posts $8.5M Q1 Loss, $183M Cash; Launches Phase 3 Depression Trial — May 13, 2026
Relmada to Showcase 12-Month Phase 2 NDV-01 Data and Phase 3 Overview — May 5, 2026
Relmada Reports $19.9M Q4 Loss, Starts Phase III Bladder Trial — Mar 20, 2026
Relmada Therapeutics Achieves 95% CR Rate and Secures $160M PIPE for Phase 3 — Mar 19, 2026
Relmada’s NDV-01 Delivers 92% Response Rate and 61% Stock Surge — Mar 9, 2026

Recent RLMD Insider Trades

TRAVERSA SERGIO bought 27.50K (~$113.30K) on Dec 15, 2025.
Shenouda Maged bought 11.66K (~$48.06K) on Dec 15, 2025.
Shenouda Maged bought 500.00K (~$1.10M) on Nov 5, 2025.

RLMD Analyst Consensus

3 analysts cover RLMD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.00.

Common questions about RLMD

Who owns RLMD stock?: Hedge funds tracked by Rallies that own RLMD include Orbimed Advisors and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Relmada Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for RLMD?: Yes. Rallies tracks hedge fund and 13F ownership data for RLMD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RLMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RLMD. It does not provide personalized investment advice.